nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0751	0.178	CbGbCtD
Afatinib—ABCG2—Hydrocortisone—psoriasis	0.0603	0.143	CbGbCtD
Afatinib—ABCG2—Cyclosporine—psoriasis	0.0569	0.135	CbGbCtD
Afatinib—ABCG2—Dexamethasone—psoriasis	0.0375	0.0889	CbGbCtD
Afatinib—ABCG2—Methotrexate—psoriasis	0.0301	0.0715	CbGbCtD
Afatinib—ABCB1—Mycophenolate mofetil—psoriasis	0.0271	0.0643	CbGbCtD
Afatinib—ABCB1—Betamethasone—psoriasis	0.0232	0.0551	CbGbCtD
Afatinib—ABCB1—Prednisolone—psoriasis	0.0229	0.0544	CbGbCtD
Afatinib—ABCB1—Hydrocortisone—psoriasis	0.0217	0.0516	CbGbCtD
Afatinib—ABCB1—Prednisone—psoriasis	0.0217	0.0514	CbGbCtD
Afatinib—ABCB1—Cyclosporine—psoriasis	0.0205	0.0487	CbGbCtD
Afatinib—ABCB1—Dexamethasone—psoriasis	0.0135	0.0321	CbGbCtD
Afatinib—ABCB1—Methotrexate—psoriasis	0.0109	0.0258	CbGbCtD
Afatinib—Vandetanib—VEGFA—psoriasis	0.00331	1	CrCbGaD
Afatinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00323	0.325	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Clobetasol propionate—psoriasis	0.000564	0.0568	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Clobetasol propionate—psoriasis	0.000535	0.054	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Fluocinonide—psoriasis	0.000451	0.0455	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Beclomethasone—psoriasis	0.000451	0.0455	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Fluocinolone Acetonide—psoriasis	0.000439	0.0442	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Fluocinonide—psoriasis	0.000429	0.0432	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Beclomethasone—psoriasis	0.000429	0.0432	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000417	0.042	CbGdCrCtD
Afatinib—Dizziness—Fluocinolone Acetonide—psoriasis	0.000359	0.00115	CcSEcCtD
Afatinib—Epistaxis—Triamcinolone—psoriasis	0.000358	0.00115	CcSEcCtD
Afatinib—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000358	0.00115	CcSEcCtD
Afatinib—Dry skin—Prednisone—psoriasis	0.000357	0.00115	CcSEcCtD
Afatinib—Mental disorder—Cyclosporine—psoriasis	0.000357	0.00115	CcSEcCtD
Afatinib—Connective tissue disorder—Hydrocortisone—psoriasis	0.000356	0.00114	CcSEcCtD
Afatinib—Infection—Mycophenolic acid—psoriasis	0.000356	0.00114	CcSEcCtD
Afatinib—Malnutrition—Cyclosporine—psoriasis	0.000355	0.00114	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—psoriasis	0.000355	0.00114	CcSEcCtD
Afatinib—Alopecia—Mycophenolate mofetil—psoriasis	0.000351	0.00113	CcSEcCtD
Afatinib—Nervous system disorder—Mycophenolic acid—psoriasis	0.000351	0.00113	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisone—psoriasis	0.00035	0.0353	CbGdCrCtD
Afatinib—Weight decreased—Betamethasone—psoriasis	0.00035	0.00112	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—psoriasis	0.00035	0.00112	CcSEcCtD
Afatinib—Mental disorder—Mycophenolate mofetil—psoriasis	0.000348	0.00112	CcSEcCtD
Afatinib—Skin disorder—Mycophenolic acid—psoriasis	0.000348	0.00112	CcSEcCtD
Afatinib—Dysgeusia—Cyclosporine—psoriasis	0.000347	0.00111	CcSEcCtD
Afatinib—Malnutrition—Mycophenolate mofetil—psoriasis	0.000346	0.00111	CcSEcCtD
Afatinib—Vomiting—Acitretin—psoriasis	0.000346	0.00111	CcSEcCtD
Afatinib—Vomiting—Fluocinolone Acetonide—psoriasis	0.000345	0.00111	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—psoriasis	0.000344	0.0011	CcSEcCtD
Afatinib—Rash—Acitretin—psoriasis	0.000343	0.0011	CcSEcCtD
Afatinib—Dermatitis—Acitretin—psoriasis	0.000343	0.0011	CcSEcCtD
Afatinib—Rash—Fluocinolone Acetonide—psoriasis	0.000342	0.0011	CcSEcCtD
Afatinib—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000342	0.0011	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisolone—psoriasis	0.000342	0.0345	CbGdCrCtD
Afatinib—Muscle spasms—Cyclosporine—psoriasis	0.000341	0.00109	CcSEcCtD
Afatinib—Headache—Acitretin—psoriasis	0.000341	0.00109	CcSEcCtD
Afatinib—Headache—Fluocinolone Acetonide—psoriasis	0.00034	0.00109	CcSEcCtD
Afatinib—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000339	0.00109	CcSEcCtD
Afatinib—Eye disorder—Hydrocortisone—psoriasis	0.000339	0.00109	CcSEcCtD
Afatinib—Body temperature increased—Hydroxyurea—psoriasis	0.000338	0.00108	CcSEcCtD
Afatinib—Conjunctivitis—Betamethasone—psoriasis	0.000335	0.00108	CcSEcCtD
Afatinib—Conjunctivitis—Dexamethasone—psoriasis	0.000335	0.00108	CcSEcCtD
Afatinib—Back pain—Mycophenolate mofetil—psoriasis	0.000335	0.00107	CcSEcCtD
Afatinib—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000333	0.00107	CcSEcCtD
Afatinib—Insomnia—Mycophenolic acid—psoriasis	0.000324	0.00104	CcSEcCtD
Afatinib—Nausea—Acitretin—psoriasis	0.000323	0.00104	CcSEcCtD
Afatinib—Nausea—Fluocinolone Acetonide—psoriasis	0.000322	0.00103	CcSEcCtD
Afatinib—Dyspnoea—Mycophenolic acid—psoriasis	0.000319	0.00102	CcSEcCtD
Afatinib—Mental disorder—Hydrocortisone—psoriasis	0.000317	0.00102	CcSEcCtD
Afatinib—Malnutrition—Hydrocortisone—psoriasis	0.000315	0.00101	CcSEcCtD
Afatinib—Dyspepsia—Mycophenolic acid—psoriasis	0.000315	0.00101	CcSEcCtD
Afatinib—Decreased appetite—Mycophenolic acid—psoriasis	0.000311	0.000998	CcSEcCtD
Afatinib—Cough—Cyclosporine—psoriasis	0.00031	0.000994	CcSEcCtD
Afatinib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000309	0.000992	CcSEcCtD
Afatinib—Fatigue—Mycophenolic acid—psoriasis	0.000309	0.00099	CcSEcCtD
Afatinib—Asthenia—Hydroxyurea—psoriasis	0.000307	0.000984	CcSEcCtD
Afatinib—Constipation—Mycophenolic acid—psoriasis	0.000306	0.000982	CcSEcCtD
Afatinib—Weight decreased—Prednisone—psoriasis	0.000305	0.000978	CcSEcCtD
Afatinib—Cough—Mycophenolate mofetil—psoriasis	0.000302	0.000969	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.0003	0.000963	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000293	0.000939	CcSEcCtD
Afatinib—Diarrhoea—Hydroxyurea—psoriasis	0.000292	0.000938	CcSEcCtD
Afatinib—Dysgeusia—Triamcinolone—psoriasis	0.000291	0.000933	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—psoriasis	0.000289	0.000928	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—psoriasis	0.000289	0.000928	CcSEcCtD
Afatinib—Infection—Cyclosporine—psoriasis	0.000288	0.000923	CcSEcCtD
Afatinib—Back pain—Triamcinolone—psoriasis	0.000287	0.000922	CcSEcCtD
Afatinib—Nervous system disorder—Cyclosporine—psoriasis	0.000284	0.000911	CcSEcCtD
Afatinib—Body temperature increased—Mycophenolic acid—psoriasis	0.000283	0.000908	CcSEcCtD
Afatinib—Dizziness—Hydroxyurea—psoriasis	0.000283	0.000907	CcSEcCtD
Afatinib—Skin disorder—Cyclosporine—psoriasis	0.000281	0.000903	CcSEcCtD
Afatinib—Infection—Mycophenolate mofetil—psoriasis	0.000281	0.000901	CcSEcCtD
Afatinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000277	0.000889	CcSEcCtD
Afatinib—Skin disorder—Mycophenolate mofetil—psoriasis	0.000274	0.00088	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—psoriasis	0.000273	0.000878	CcSEcCtD
Afatinib—Alopecia—Betamethasone—psoriasis	0.000273	0.000878	CcSEcCtD
Afatinib—Vomiting—Hydroxyurea—psoriasis	0.000272	0.000872	CcSEcCtD
Afatinib—Rash—Hydroxyurea—psoriasis	0.000269	0.000865	CcSEcCtD
Afatinib—Dermatitis—Hydroxyurea—psoriasis	0.000269	0.000864	CcSEcCtD
Afatinib—Headache—Hydroxyurea—psoriasis	0.000268	0.000859	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000267	0.000856	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—psoriasis	0.000265	0.00085	CcSEcCtD
Afatinib—Insomnia—Cyclosporine—psoriasis	0.000262	0.00084	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—psoriasis	0.000262	0.000839	CcSEcCtD
Afatinib—Cough—Triamcinolone—psoriasis	0.000259	0.000831	CcSEcCtD
Afatinib—Dyspnoea—Cyclosporine—psoriasis	0.000258	0.000828	CcSEcCtD
Afatinib—Asthenia—Mycophenolic acid—psoriasis	0.000257	0.000824	CcSEcCtD
Afatinib—Infection—Hydrocortisone—psoriasis	0.000256	0.00082	CcSEcCtD
Afatinib—Insomnia—Mycophenolate mofetil—psoriasis	0.000255	0.00082	CcSEcCtD
Afatinib—Dyspepsia—Cyclosporine—psoriasis	0.000255	0.000818	CcSEcCtD
Afatinib—Nausea—Hydroxyurea—psoriasis	0.000254	0.000815	CcSEcCtD
Afatinib—Pruritus—Mycophenolic acid—psoriasis	0.000253	0.000813	CcSEcCtD
Afatinib—Nervous system disorder—Hydrocortisone—psoriasis	0.000252	0.00081	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—psoriasis	0.000252	0.00081	CcSEcCtD
Afatinib—Eye disorder—Prednisone—psoriasis	0.000252	0.000808	CcSEcCtD
Afatinib—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000252	0.000808	CcSEcCtD
Afatinib—Decreased appetite—Cyclosporine—psoriasis	0.000252	0.000808	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—psoriasis	0.000251	0.000805	CcSEcCtD
Afatinib—Infestation—Methotrexate—psoriasis	0.000251	0.000805	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00025	0.000802	CcSEcCtD
Afatinib—Skin disorder—Hydrocortisone—psoriasis	0.00025	0.000802	CcSEcCtD
Afatinib—Fatigue—Cyclosporine—psoriasis	0.00025	0.000801	CcSEcCtD
Afatinib—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000249	0.000798	CcSEcCtD
Afatinib—Constipation—Cyclosporine—psoriasis	0.000248	0.000795	CcSEcCtD
Afatinib—Renal failure—Methotrexate—psoriasis	0.000247	0.000791	CcSEcCtD
Afatinib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000246	0.000788	CcSEcCtD
Afatinib—Diarrhoea—Mycophenolic acid—psoriasis	0.000245	0.000786	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—psoriasis	0.000245	0.000785	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—psoriasis	0.000244	0.000783	CcSEcCtD
Afatinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000244	0.000783	CcSEcCtD
Afatinib—Constipation—Mycophenolate mofetil—psoriasis	0.000242	0.000775	CcSEcCtD
Afatinib—Infection—Triamcinolone—psoriasis	0.000241	0.000772	CcSEcCtD
Afatinib—Insomnia—Prednisolone—psoriasis	0.000238	0.000765	CcSEcCtD
Afatinib—Alopecia—Prednisone—psoriasis	0.000238	0.000764	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—psoriasis	0.000237	0.000761	CcSEcCtD
Afatinib—Dizziness—Mycophenolic acid—psoriasis	0.000237	0.00076	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—psoriasis	0.000237	0.000759	CcSEcCtD
Afatinib—Mental disorder—Prednisone—psoriasis	0.000236	0.000758	CcSEcCtD
Afatinib—Malnutrition—Prednisone—psoriasis	0.000235	0.000753	CcSEcCtD
Afatinib—Insomnia—Hydrocortisone—psoriasis	0.000233	0.000747	CcSEcCtD
Afatinib—Body temperature increased—Cyclosporine—psoriasis	0.000229	0.000735	CcSEcCtD
Afatinib—Vomiting—Mycophenolic acid—psoriasis	0.000228	0.00073	CcSEcCtD
Afatinib—Dyspepsia—Hydrocortisone—psoriasis	0.000227	0.000727	CcSEcCtD
Afatinib—Rash—Mycophenolic acid—psoriasis	0.000226	0.000724	CcSEcCtD
Afatinib—Dermatitis—Mycophenolic acid—psoriasis	0.000225	0.000724	CcSEcCtD
Afatinib—Headache—Mycophenolic acid—psoriasis	0.000224	0.00072	CcSEcCtD
Afatinib—Decreased appetite—Hydrocortisone—psoriasis	0.000224	0.000718	CcSEcCtD
Afatinib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000223	0.000717	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—psoriasis	0.000222	0.000714	CcSEcCtD
Afatinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000222	0.000713	CcSEcCtD
Afatinib—Fatigue—Hydrocortisone—psoriasis	0.000222	0.000712	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Hydrocortisone—psoriasis	0.000222	0.0223	CbGdCrCtD
Afatinib—Urethral disorder—Methotrexate—psoriasis	0.000221	0.000709	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—psoriasis	0.000219	0.000703	CcSEcCtD
Afatinib—Infection—Dexamethasone—psoriasis	0.000218	0.000701	CcSEcCtD
Afatinib—Infection—Betamethasone—psoriasis	0.000218	0.000701	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—psoriasis	0.000216	0.000693	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—psoriasis	0.000216	0.000692	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—psoriasis	0.000216	0.000692	CcSEcCtD
Afatinib—Dyspepsia—Triamcinolone—psoriasis	0.000213	0.000684	CcSEcCtD
Afatinib—Nausea—Mycophenolic acid—psoriasis	0.000213	0.000682	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—psoriasis	0.00021	0.000675	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Hydrocortisone—psoriasis	0.00021	0.0212	CbGdCrCtD
Afatinib—Fatigue—Triamcinolone—psoriasis	0.000209	0.00067	CcSEcCtD
Afatinib—Asthenia—Cyclosporine—psoriasis	0.000208	0.000667	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—psoriasis	0.000206	0.0207	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—psoriasis	0.000206	0.0207	CbGdCrCtD
Afatinib—Pruritus—Cyclosporine—psoriasis	0.000205	0.000657	CcSEcCtD
Afatinib—Body temperature increased—Hydrocortisone—psoriasis	0.000203	0.000653	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—psoriasis	0.000203	0.000651	CcSEcCtD
Afatinib—Asthenia—Mycophenolate mofetil—psoriasis	0.000203	0.00065	CcSEcCtD
Afatinib—Pruritus—Mycophenolate mofetil—psoriasis	0.0002	0.000641	CcSEcCtD
Afatinib—Alopecia—Methotrexate—psoriasis	0.000199	0.000639	CcSEcCtD
Afatinib—Insomnia—Betamethasone—psoriasis	0.000199	0.000638	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—psoriasis	0.000199	0.000638	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000198	0.000637	CcSEcCtD
Afatinib—Diarrhoea—Cyclosporine—psoriasis	0.000198	0.000636	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—psoriasis	0.000197	0.000633	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—psoriasis	0.000196	0.000629	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—psoriasis	0.000195	0.0197	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—psoriasis	0.000195	0.0197	CbGdCrCtD
Afatinib—Dyspepsia—Betamethasone—psoriasis	0.000194	0.000621	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—psoriasis	0.000194	0.000621	CcSEcCtD
Afatinib—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000193	0.00062	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—psoriasis	0.000192	0.000616	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—psoriasis	0.000192	0.000615	CcSEcCtD
Afatinib—Dizziness—Cyclosporine—psoriasis	0.000191	0.000614	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—psoriasis	0.000191	0.000613	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—psoriasis	0.000191	0.000613	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—psoriasis	0.000191	0.0193	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—psoriasis	0.000191	0.0192	CbGdCrCtD
Afatinib—Infection—Prednisone—psoriasis	0.00019	0.00061	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00019	0.000609	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—psoriasis	0.00019	0.000609	CcSEcCtD
Afatinib—Back pain—Methotrexate—psoriasis	0.00019	0.000609	CcSEcCtD
Afatinib—Fatigue—Betamethasone—psoriasis	0.00019	0.000608	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—psoriasis	0.00019	0.000608	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—psoriasis	0.000188	0.000603	CcSEcCtD
Afatinib—Dizziness—Mycophenolate mofetil—psoriasis	0.000187	0.000599	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisolone—psoriasis	0.000186	0.0188	CbGdCrCtD
Afatinib—Skin disorder—Prednisone—psoriasis	0.000186	0.000597	CcSEcCtD
Afatinib—Asthenia—Hydrocortisone—psoriasis	0.000185	0.000592	CcSEcCtD
Afatinib—Vomiting—Cyclosporine—psoriasis	0.000184	0.000591	CcSEcCtD
Afatinib—Rash—Cyclosporine—psoriasis	0.000183	0.000586	CcSEcCtD
Afatinib—Dermatitis—Cyclosporine—psoriasis	0.000182	0.000585	CcSEcCtD
Afatinib—Pruritus—Hydrocortisone—psoriasis	0.000182	0.000584	CcSEcCtD
Afatinib—Headache—Cyclosporine—psoriasis	0.000181	0.000582	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—psoriasis	0.000181	0.0183	CbGdCrCtD
Afatinib—Vomiting—Mycophenolate mofetil—psoriasis	0.00018	0.000576	CcSEcCtD
Afatinib—Rash—Mycophenolate mofetil—psoriasis	0.000178	0.000572	CcSEcCtD
Afatinib—Dermatitis—Mycophenolate mofetil—psoriasis	0.000178	0.000571	CcSEcCtD
Afatinib—Headache—Mycophenolate mofetil—psoriasis	0.000177	0.000568	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisolone—psoriasis	0.000177	0.0178	CbGdCrCtD
Afatinib—Diarrhoea—Hydrocortisone—psoriasis	0.000176	0.000565	CcSEcCtD
Afatinib—Dizziness—Prednisolone—psoriasis	0.000174	0.000559	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—psoriasis	0.000174	0.000558	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—psoriasis	0.000174	0.000558	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—psoriasis	0.000174	0.000558	CcSEcCtD
Afatinib—Insomnia—Prednisone—psoriasis	0.000173	0.000556	CcSEcCtD
Afatinib—Nausea—Cyclosporine—psoriasis	0.000172	0.000552	CcSEcCtD
Afatinib—Pruritus—Triamcinolone—psoriasis	0.000171	0.00055	CcSEcCtD
Afatinib—Cough—Methotrexate—psoriasis	0.000171	0.000549	CcSEcCtD
Afatinib—Dizziness—Hydrocortisone—psoriasis	0.00017	0.000546	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—psoriasis	0.000169	0.000541	CcSEcCtD
Afatinib—Nausea—Mycophenolate mofetil—psoriasis	0.000168	0.000538	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—psoriasis	0.000166	0.000534	CcSEcCtD
Afatinib—Rash—Prednisolone—psoriasis	0.000166	0.000533	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—psoriasis	0.000166	0.000533	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000166	0.000532	CcSEcCtD
Afatinib—Fatigue—Prednisone—psoriasis	0.000165	0.00053	CcSEcCtD
Afatinib—Headache—Prednisolone—psoriasis	0.000165	0.00053	CcSEcCtD
Afatinib—Constipation—Prednisone—psoriasis	0.000164	0.000525	CcSEcCtD
Afatinib—Vomiting—Hydrocortisone—psoriasis	0.000164	0.000525	CcSEcCtD
Afatinib—Rash—Hydrocortisone—psoriasis	0.000162	0.000521	CcSEcCtD
Afatinib—Dermatitis—Hydrocortisone—psoriasis	0.000162	0.00052	CcSEcCtD
Afatinib—Headache—Hydrocortisone—psoriasis	0.000161	0.000517	CcSEcCtD
Afatinib—Dizziness—Triamcinolone—psoriasis	0.00016	0.000514	CcSEcCtD
Afatinib—Infection—Methotrexate—psoriasis	0.000159	0.00051	CcSEcCtD
Afatinib—Asthenia—Betamethasone—psoriasis	0.000158	0.000506	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—psoriasis	0.000158	0.000506	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—psoriasis	0.000157	0.000504	CcSEcCtD
Afatinib—Nausea—Prednisolone—psoriasis	0.000157	0.000502	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—psoriasis	0.000156	0.000499	CcSEcCtD
Afatinib—Pruritus—Betamethasone—psoriasis	0.000156	0.000499	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—psoriasis	0.000155	0.000499	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—psoriasis	0.000154	0.000494	CcSEcCtD
Afatinib—Nausea—Hydrocortisone—psoriasis	0.000153	0.000491	CcSEcCtD
Afatinib—Rash—Triamcinolone—psoriasis	0.000153	0.00049	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—psoriasis	0.000153	0.00049	CcSEcCtD
Afatinib—Headache—Triamcinolone—psoriasis	0.000152	0.000487	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—psoriasis	0.000151	0.000486	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—psoriasis	0.00015	0.000483	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—psoriasis	0.00015	0.000483	CcSEcCtD
Afatinib—Dizziness—Dexamethasone—psoriasis	0.000145	0.000467	CcSEcCtD
Afatinib—Dizziness—Betamethasone—psoriasis	0.000145	0.000467	CcSEcCtD
Afatinib—Insomnia—Methotrexate—psoriasis	0.000145	0.000464	CcSEcCtD
Afatinib—Nausea—Triamcinolone—psoriasis	0.000144	0.000462	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—psoriasis	0.000143	0.000458	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—psoriasis	0.000141	0.000452	CcSEcCtD
Afatinib—Vomiting—Betamethasone—psoriasis	0.00014	0.000449	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—psoriasis	0.00014	0.000449	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—psoriasis	0.000139	0.000446	CcSEcCtD
Afatinib—Rash—Dexamethasone—psoriasis	0.000139	0.000445	CcSEcCtD
Afatinib—Rash—Betamethasone—psoriasis	0.000139	0.000445	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—psoriasis	0.000139	0.000444	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—psoriasis	0.000139	0.000444	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—psoriasis	0.000138	0.000443	CcSEcCtD
Afatinib—Fatigue—Methotrexate—psoriasis	0.000138	0.000443	CcSEcCtD
Afatinib—Headache—Betamethasone—psoriasis	0.000138	0.000442	CcSEcCtD
Afatinib—Headache—Dexamethasone—psoriasis	0.000138	0.000442	CcSEcCtD
Afatinib—Asthenia—Prednisone—psoriasis	0.000137	0.000441	CcSEcCtD
Afatinib—Pruritus—Prednisone—psoriasis	0.000135	0.000435	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—psoriasis	0.000131	0.00042	CcSEcCtD
Afatinib—Nausea—Betamethasone—psoriasis	0.000131	0.000419	CcSEcCtD
Afatinib—Nausea—Dexamethasone—psoriasis	0.000131	0.000419	CcSEcCtD
Afatinib—Dizziness—Prednisone—psoriasis	0.000127	0.000406	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—psoriasis	0.000127	0.000406	CcSEcCtD
Afatinib—ERBB2—Levonorgestrel—Hydrocortisone—psoriasis	0.000123	0.0124	CbGdCrCtD
Afatinib—Vomiting—Prednisone—psoriasis	0.000122	0.000391	CcSEcCtD
Afatinib—Rash—Prednisone—psoriasis	0.000121	0.000387	CcSEcCtD
Afatinib—Dermatitis—Prednisone—psoriasis	0.000121	0.000387	CcSEcCtD
Afatinib—Headache—Prednisone—psoriasis	0.00012	0.000385	CcSEcCtD
Afatinib—Asthenia—Methotrexate—psoriasis	0.000115	0.000368	CcSEcCtD
Afatinib—Nausea—Prednisone—psoriasis	0.000114	0.000365	CcSEcCtD
Afatinib—Pruritus—Methotrexate—psoriasis	0.000113	0.000363	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—psoriasis	0.000109	0.000351	CcSEcCtD
Afatinib—Dizziness—Methotrexate—psoriasis	0.000106	0.00034	CcSEcCtD
Afatinib—Vomiting—Methotrexate—psoriasis	0.000102	0.000326	CcSEcCtD
Afatinib—Rash—Methotrexate—psoriasis	0.000101	0.000324	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—psoriasis	0.000101	0.000323	CcSEcCtD
Afatinib—Headache—Methotrexate—psoriasis	0.0001	0.000322	CcSEcCtD
Afatinib—Nausea—Methotrexate—psoriasis	9.51e-05	0.000305	CcSEcCtD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	4.53e-05	0.000179	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—IL6—psoriasis	4.53e-05	0.000179	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—IL6—psoriasis	4.49e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-E—psoriasis	4.46e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	4.45e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	4.43e-05	0.000175	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—IL6—psoriasis	4.43e-05	0.000175	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—STAT3—psoriasis	4.42e-05	0.000174	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-A—psoriasis	4.4e-05	0.000174	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NFKBIA—psoriasis	4.39e-05	0.000173	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL20—psoriasis	4.37e-05	0.000172	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	4.37e-05	0.000172	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—IL6—psoriasis	4.37e-05	0.000172	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—IL6—psoriasis	4.37e-05	0.000172	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—JUN—psoriasis	4.36e-05	0.000172	CbGpPWpGaD
Afatinib—ABL1—Immune System—SOCS1—psoriasis	4.36e-05	0.000172	CbGpPWpGaD
Afatinib—ERBB2—Immune System—TYK2—psoriasis	4.34e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—STAT3—psoriasis	4.33e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—IL6—psoriasis	4.33e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-E—psoriasis	4.29e-05	0.000169	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—IL6—psoriasis	4.29e-05	0.000169	CbGpPWpGaD
Afatinib—ERBB4—Immune System—TYK2—psoriasis	4.27e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DRB1—psoriasis	4.27e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—IL6—psoriasis	4.27e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—STAT3—psoriasis	4.26e-05	0.000168	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ICAM1—psoriasis	4.25e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NFKBIA—psoriasis	4.23e-05	0.000167	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NFKBIA—psoriasis	4.22e-05	0.000166	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—TYK2—psoriasis	4.21e-05	0.000166	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL20—psoriasis	4.21e-05	0.000166	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CRP—psoriasis	4.2e-05	0.000166	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—NFKB1—psoriasis	4.19e-05	0.000165	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CARM1—psoriasis	4.15e-05	0.000164	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—IL6—psoriasis	4.12e-05	0.000163	CbGpPWpGaD
Afatinib—BLK—Immune System—TYK2—psoriasis	4.11e-05	0.000162	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ICAM1—psoriasis	4.1e-05	0.000162	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TYK2—psoriasis	4.08e-05	0.000161	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NFKBIA—psoriasis	4.07e-05	0.00016	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IFNG—psoriasis	4.06e-05	0.00016	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—VEGFA—psoriasis	4.04e-05	0.000159	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DRB1—psoriasis	4.02e-05	0.000159	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.01e-05	0.000158	CbGpPWpGaD
Afatinib—ERBB2—Disease—TYK2—psoriasis	4e-05	0.000158	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IFNG—psoriasis	4e-05	0.000158	CbGpPWpGaD
Afatinib—PHKG2—Disease—IL6—psoriasis	3.95e-05	0.000156	CbGpPWpGaD
Afatinib—ERBB4—Disease—TYK2—psoriasis	3.94e-05	0.000156	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD4—psoriasis	3.92e-05	0.000155	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.88e-05	0.000153	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	3.87e-05	0.000153	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD4—psoriasis	3.86e-05	0.000152	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD8A—psoriasis	3.86e-05	0.000152	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ICAM1—psoriasis	3.86e-05	0.000152	CbGpPWpGaD
Afatinib—BLK—Immune System—IFNG—psoriasis	3.85e-05	0.000152	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NFKBIA—psoriasis	3.83e-05	0.000151	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD4—psoriasis	3.81e-05	0.00015	CbGpPWpGaD
Afatinib—EGFR—Immune System—SOCS1—psoriasis	3.72e-05	0.000147	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NFKB1—psoriasis	3.72e-05	0.000147	CbGpPWpGaD
Afatinib—BLK—Immune System—CD4—psoriasis	3.72e-05	0.000147	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-B—psoriasis	3.72e-05	0.000147	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—LEP—psoriasis	3.67e-05	0.000145	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—APOE—psoriasis	3.67e-05	0.000145	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—psoriasis	3.64e-05	0.000144	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD4—psoriasis	3.62e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—APOE—psoriasis	3.62e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—LEP—psoriasis	3.62e-05	0.000143	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—TYK2—psoriasis	3.6e-05	0.000142	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SOCS1—psoriasis	3.6e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—psoriasis	3.59e-05	0.000141	CbGpPWpGaD
Afatinib—LCK—Immune System—SOCS1—psoriasis	3.59e-05	0.000141	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD4—psoriasis	3.57e-05	0.000141	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.56e-05	0.00014	CbGpPWpGaD
Afatinib—ERBB2—Immune System—JUN—psoriasis	3.51e-05	0.000138	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—TYK2—psoriasis	3.47e-05	0.000137	CbGpPWpGaD
Afatinib—ERBB4—Immune System—JUN—psoriasis	3.46e-05	0.000136	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-A—psoriasis	3.44e-05	0.000136	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.43e-05	0.000135	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKBIA—psoriasis	3.42e-05	0.000135	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—JUN—psoriasis	3.41e-05	0.000134	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NFKB1—psoriasis	3.38e-05	0.000133	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—VEGFA—psoriasis	3.37e-05	0.000133	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKBIA—psoriasis	3.37e-05	0.000133	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—STAT3—psoriasis	3.34e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NFKB1—psoriasis	3.33e-05	0.000131	CbGpPWpGaD
Afatinib—BLK—Immune System—JUN—psoriasis	3.33e-05	0.000131	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—VEGFA—psoriasis	3.31e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD8A—psoriasis	3.3e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Immune System—CRP—psoriasis	3.28e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NFKB1—psoriasis	3.28e-05	0.000129	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—psoriasis	3.27e-05	0.000129	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—psoriasis	3.25e-05	0.000128	CbGpPWpGaD
Afatinib—BLK—Immune System—NFKB1—psoriasis	3.2e-05	0.000126	CbGpPWpGaD
Afatinib—LCK—Immune System—CD8A—psoriasis	3.18e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NFKB1—psoriasis	3.18e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—psoriasis	3.18e-05	0.000125	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DRB1—psoriasis	3.15e-05	0.000124	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—psoriasis	3.14e-05	0.000124	CbGpPWpGaD
Afatinib—IRAK1—Immune System—TYK2—psoriasis	3.13e-05	0.000124	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—psoriasis	3.13e-05	0.000123	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.11e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—psoriasis	3.09e-05	0.000122	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—psoriasis	3.06e-05	0.000121	CbGpPWpGaD
Afatinib—ERBB2—Immune System—STAT3—psoriasis	3.04e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—psoriasis	3.02e-05	0.000119	CbGpPWpGaD
Afatinib—ABL1—Immune System—ICAM1—psoriasis	3.02e-05	0.000119	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—psoriasis	3.01e-05	0.000119	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKBIA—psoriasis	2.99e-05	0.000118	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—psoriasis	2.99e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—psoriasis	2.97e-05	0.000117	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-A—psoriasis	2.94e-05	0.000116	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—psoriasis	2.94e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—JUN—psoriasis	2.91e-05	0.000115	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—psoriasis	2.89e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—psoriasis	2.88e-05	0.000114	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—psoriasis	2.88e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—psoriasis	2.85e-05	0.000113	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—psoriasis	2.84e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-A—psoriasis	2.84e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—JUN—psoriasis	2.81e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—psoriasis	2.81e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NFKB1—psoriasis	2.8e-05	0.000111	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TYK2—psoriasis	2.8e-05	0.000111	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—psoriasis	2.8e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—psoriasis	2.79e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TYK2—psoriasis	2.76e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—psoriasis	2.76e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—psoriasis	2.72e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Disease—HLA-A—psoriasis	2.72e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—psoriasis	2.7e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NFKB1—psoriasis	2.7e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NFKB1—psoriasis	2.69e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—psoriasis	2.69e-05	0.000106	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.67e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—psoriasis	2.66e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—LEP—psoriasis	2.66e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—psoriasis	2.63e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Disease—HLA-A—psoriasis	2.62e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NFKB1—psoriasis	2.59e-05	0.000102	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—psoriasis	2.59e-05	0.000102	CbGpPWpGaD
Afatinib—EGFR—Immune System—ICAM1—psoriasis	2.58e-05	0.000102	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKBIA—psoriasis	2.56e-05	0.000101	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAT—psoriasis	2.55e-05	0.000101	CbGpPWpGaD
Afatinib—IRAK1—Immune System—JUN—psoriasis	2.54e-05	0.0001	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—psoriasis	2.54e-05	0.0001	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—psoriasis	2.5e-05	9.86e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—psoriasis	2.49e-05	9.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKBIA—psoriasis	2.47e-05	9.76e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—psoriasis	2.47e-05	9.74e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKBIA—psoriasis	2.47e-05	9.73e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TYK2—psoriasis	2.45e-05	9.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—psoriasis	2.44e-05	9.64e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NFKB1—psoriasis	2.44e-05	9.63e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—psoriasis	2.44e-05	9.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SOCS1—psoriasis	2.41e-05	9.49e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—psoriasis	2.4e-05	9.48e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—psoriasis	2.36e-05	9.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.35e-05	9.27e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—psoriasis	2.33e-05	9.2e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SOCS1—psoriasis	2.32e-05	9.15e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—psoriasis	2.3e-05	9.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—TYK2—psoriasis	2.29e-05	9.05e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—psoriasis	2.28e-05	8.98e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—JUN—psoriasis	2.27e-05	8.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CARM1—psoriasis	2.24e-05	8.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—JUN—psoriasis	2.24e-05	8.82e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—psoriasis	2.22e-05	8.75e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—psoriasis	2.2e-05	8.66e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKB1—psoriasis	2.18e-05	8.62e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKB1—psoriasis	2.15e-05	8.49e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—psoriasis	2.12e-05	8.36e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TYK2—psoriasis	2.1e-05	8.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—psoriasis	2.09e-05	8.24e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—psoriasis	2.06e-05	8.12e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—psoriasis	2.06e-05	8.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TYK2—psoriasis	2.03e-05	7.99e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TYK2—psoriasis	2.02e-05	7.97e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—psoriasis	2.01e-05	7.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—psoriasis	2e-05	7.88e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—psoriasis	1.99e-05	7.86e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—psoriasis	1.99e-05	7.83e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—psoriasis	1.98e-05	7.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—psoriasis	1.98e-05	7.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—psoriasis	1.96e-05	7.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—psoriasis	1.96e-05	7.74e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—psoriasis	1.96e-05	7.72e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—psoriasis	1.95e-05	7.7e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TYK2—psoriasis	1.94e-05	7.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—psoriasis	1.93e-05	7.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—psoriasis	1.93e-05	7.61e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKB1—psoriasis	1.91e-05	7.54e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—psoriasis	1.9e-05	7.48e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—psoriasis	1.89e-05	7.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TYK2—psoriasis	1.87e-05	7.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—psoriasis	1.83e-05	7.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—psoriasis	1.78e-05	7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—psoriasis	1.78e-05	7e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	1.76e-05	6.96e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—psoriasis	1.76e-05	6.94e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—psoriasis	1.75e-05	6.9e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—psoriasis	1.73e-05	6.81e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—psoriasis	1.72e-05	6.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—psoriasis	1.71e-05	6.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—psoriasis	1.71e-05	6.75e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—psoriasis	1.7e-05	6.69e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—psoriasis	1.7e-05	6.69e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—psoriasis	1.69e-05	6.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKBIA—psoriasis	1.65e-05	6.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—psoriasis	1.64e-05	6.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—psoriasis	1.64e-05	6.45e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—psoriasis	1.63e-05	6.44e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKBIA—psoriasis	1.59e-05	6.29e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	1.58e-05	6.23e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—psoriasis	1.57e-05	6.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—psoriasis	1.53e-05	6.05e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—psoriasis	1.5e-05	5.91e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—psoriasis	1.48e-05	5.82e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—psoriasis	1.47e-05	5.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	1.43e-05	5.65e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—psoriasis	1.42e-05	5.6e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—psoriasis	1.41e-05	5.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—psoriasis	1.38e-05	5.44e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—psoriasis	1.37e-05	5.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TYK2—psoriasis	1.36e-05	5.35e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—psoriasis	1.36e-05	5.34e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—psoriasis	1.35e-05	5.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TYK2—psoriasis	1.31e-05	5.15e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—psoriasis	1.31e-05	5.15e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—psoriasis	1.2e-05	4.73e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—psoriasis	1.18e-05	4.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—psoriasis	1.14e-05	4.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—psoriasis	1.12e-05	4.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—psoriasis	1.1e-05	4.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—psoriasis	1.08e-05	4.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—psoriasis	1.07e-05	4.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—psoriasis	1.06e-05	4.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—psoriasis	1.06e-05	4.16e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—psoriasis	1.03e-05	4.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—psoriasis	1.02e-05	4.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—psoriasis	9.91e-06	3.91e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—psoriasis	9.88e-06	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—psoriasis	9.58e-06	3.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—psoriasis	9.49e-06	3.74e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—psoriasis	9.47e-06	3.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—psoriasis	9.34e-06	3.68e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—psoriasis	9.24e-06	3.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—psoriasis	9.14e-06	3.61e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—psoriasis	9.12e-06	3.6e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—psoriasis	7.24e-06	2.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—psoriasis	6.98e-06	2.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—psoriasis	6.63e-06	2.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—psoriasis	6.39e-06	2.52e-05	CbGpPWpGaD
